Protagonist Therapeutics, Inc.

NasdaqGM:PTGX Stock Report

Market Cap: US$2.9b

Protagonist Therapeutics Dividend

Dividend criteria checks 0/6

Protagonist Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield1.9%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per shareUS$2.89
Future Dividend Yieldn/a

Recent dividend updates

No updates

Recent updates

The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey

Oct 16

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

Apr 13
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Feb 25

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Dec 28
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Jul 04
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 20
Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

Feb 06
An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Jun 15
We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Protagonist: Too Many Red Flags

Jun 08

Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

May 11
Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

Protagonist Is Still Being Undervalued Like There's Real Risk

Feb 01

Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Jan 04
Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates

Aug 06
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year

Jun 19
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year

Protagonist Therapeutics closes $132M capital raise

Jun 18

Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy

Jun 03

This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet

May 21
This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet

Protagonist EPS beats by $0.03, beats on revenue

May 04

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if PTGX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PTGX's dividend payments have been increasing.


Dividend Yield vs Market

Protagonist Therapeutics Dividend Yield vs Market
How does PTGX dividend yield compare to the market?
SegmentDividend Yield
Company (PTGX)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.4%
Industry Average (Biotechs)1.9%
Analyst forecast (PTGX) (up to 3 years)n/a

Notable Dividend: Unable to evaluate PTGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PTGX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate PTGX's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PTGX has not reported any payouts.


Discover strong dividend paying companies